Cristina Georgiana Croitoru

Dr. Cristina Georgiana Croitoru


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
TSThomas-Gabriel Schreiner
Thomas-Gabriel Schreiner
CCCristina Georgiana Croitoru
Cristina Georgiana Croitoru
DHDiana Nicoleta Hodorog
Diana Nicoleta Hodorog
DCDan Iulian Cuciureanu
Dan Iulian Cuciureanu
Alzheimer’s disease, the most common type of dementia worldwide, lacks effective disease-modifying therapies despite significant research efforts. Passive anti-amyloid immunotherapies represent a promising avenue for Alzheimer’s disease treatment by targeting the amyloid-beta peptide, a key pathological hallmark of the disease. This approach utilizes monoclonal antibodies designed to specifically bind amyloid beta, facilitating its clearance from the brain. This review offers an original and critical analysis of anti-amyloid immunotherapies by exploring several aspects. Firstly, the mechanisms of action of these therapies are reviewed, focusing on their ability to promote Aβ degradation and enhance its efflux from the central nervous system. Subsequently, the extensive history of clinical trials involving anti-amyloid antibodies is presented, from initial efforts using first-generation molecules leading to mixed results to recent clinically approved drugs. Along with undeniable progress, the authors also highlight the pitfalls of this approach to offer a balanced perspective on this topic. Finally, based on its potential and limitations, the future directions of this promising therapeutic strategy for Alzheimer’s disease are emphasized.

14 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCCristina Georgiana Croitoru
Cristina Georgiana Croitoru
MPMariana Pavel-Tanasa
Mariana Pavel-Tanasa
Dan Iulian CuciureanuDan Iulian Cuciureanu
Dan Iulian Cuciureanu
DHDiana Nicoleta Hodorog
Diana Nicoleta Hodorog
PCPetru Cianga
Petru Cianga
Background: As the life expectancy of patients with myasthenia gravis (MG) is improving, so the number of comorbidities continues to rise, with a potentially significant impact on the overall morbidity and mortality. The main aim of the study was to assess comorbidities of MG in a group of patients of East-European descent. Methods: We retrospectively compared 185 adult myasthenic patients with 895 sex- and age-matched controls, admitted from January 2013 to December 2021. Results: Of these patients, 60% had late-onset MG (LOMG), with a clear predominance of women in both the LOMG and early-onset (EOMG) types; and 23.8% of the patients had a radiological description consistent with thymoma. All myasthenic patients had at least one comorbidity; 20 (10.8%) of the patients associated at least one autoimmune comorbidity. Obesity (p < 0.01), type 2 diabetes (p < 0.0001), cerebrovascular diseases (p < 0.0001), essential hypertension (p < 0.01), and cardiac arrythmias (p < 0.0001) were more frequent in patients than in the control group. The granulocyte-to-lymphocyte ratio was higher in the myasthenic patients compared to the controls (p < 0.01 for LOMG). Discussion: We, thus, suggest a common chronic low-grade inflammatory background as a possible connection between MG subtypes and some of these apparently unconnected comorbidities. Conclusions: The East-European origin of the patients offered a different social and cultural angle of a disease studied mainly on populations of West-European and Asian descent.

10 December 2024 in Neurology International
Verified
Journal Article
Open access
PDF file
CCCristina Georgiana Croitoru
Cristina Georgiana Croitoru
DCDaniela Constantinescu
Daniela Constantinescu
MPMariana Pavel-Tanasa
Mariana Pavel-Tanasa
Dan Iulian CuciureanuDan Iulian Cuciureanu
Dan Iulian Cuciureanu
CCCorina Maria Cianga
Corina Maria Cianga
PCPetru Cianga
Petru Cianga
Background: Several significant associations between certain Human Leukocyte Antigen (HLA) alleles and myasthenia gravis (MG) subtypes were established in populations from Western Europe and North America and, to a lesser extent, from China and Japan. However, such data are scarcely available for Eastern Europe. This study aimed to analyze the associations of HLA Class I and II alleles with MG and its serological subtypes (with anti-acetylcholine receptor autoantibodies, RAch+MG, and double-seronegative, dSNMG) in myasthenic patients of Romanian descent. Methods: We consecutively enrolled adult Romanian unrelated myasthenic patients, which were genotyped by next-generation sequencing for HLA-A, -B, -C, -DRB1 and -DQB1. The descent-matched controls were represented by two separate groups of random normal subjects genotyped for the main five HLA loci at the two-digit and four-digit levels, respectively, collected from the Allele Frequency Net Database. Results: A total of 40 patients (females: 80.00%; median age at onset: 42.5 years, range: 1–78; RAch+MG: 75.00%; dSNMG: 22.50%) were included. We were able to confirm previously acknowledged allelic associations: positive for HLA-B*08, DRB1*14:54 and DRB1*16:01 and negative for DRB1*13. However, we found some potential novel significant positive associations between MG and the HLA-A*02:36, B*47, B*73, B*44:27 and B*57:02 alleles. All alleles positively associated with MG remained significantly associated with RAch+MG, regardless of the patients’ clinical and thymic heterogeneity. We found significant positive associations between dSNMG and the HLA-B*47, B*44:27 and DRB1*14:54 alleles that are shared with RAch+MG. Conclusions: These results suggest both distinct and common etiopathogenic mechanisms between dSNMG and RAch+MG. Our study pioneers allele associations in Romanian MG patients.

12 January 2025 in Sclerosis
Verified
Journal Article
Open access
PDF file
TSThomas-Gabriel Schreiner
Thomas-Gabriel Schreiner
IGIacob Liviu Gabriel
Iacob Liviu Gabriel
CCCristina Georgiana Croitoru
Cristina Georgiana Croitoru
DHDiana Nicoleta Hodorog
Diana Nicoleta Hodorog
DCDan Iulian Cuciureanu
Dan Iulian Cuciureanu
Background: Amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are, in essence, neurodegenerative disorders with significant individual, social, and economic burdens worldwide. Despite having different clinical onset and evolution, the two diseases share common risk factors and underlying pathophysiological mechanisms. Environmental risk factors are particularly interesting, considering the available effective counter strategies. High-fat diets remain a significant element that negatively impacts the onset and evolution of several disorders, including ALS and MS. Focusing on changeable disease-related aspects is increasingly appealing in the context of a lack of an effective treatment. Methods: This review aims to offer an updated overview of the influence of high-fat diets in modulating the risk of onset and progression of ALS and MS, based on the search of three relevant online databases. Results: In the first part, the shared pathophysiological mechanisms of ALS and MS are shown, and significant differences between the two disorders are highlighted. Subsequently, the most relevant research on this topic conducted in animal models and humans is presented, bringing additional proof of the critical role of high-fat diets in neurodegeneration. Finally, based on current knowledge, the authors offer potential therapeutic approaches and future relevant research directions to better control nutrition in ALS and MS patients, hoping to increase survival and quality of life. Conclusions: High-fat diets negatively impact the onset and evolution of ALS and MS.